Anping Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anping Xu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Ling Ji
Department of Laboratory Medicine , 74573 Peking University Shenzhen Hospital , Shenzhen , Guangdong , P.R. China
18 shared publications Weijie Xie
Department of Laboratory Medicine, Peking University Shenzhen Hospital
13 shared publicationsLing Ji
Department of Laboratory Medicine, Peking University Shenzhen Hospital
11 shared publicationsJie Li
Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, P.R. China
10 shared publicationsWeidong Chen
Department of Laboratory Medicine, Peking University Shenzhen Hospital , Shenzhen, Guangdong , China
9 shared publicationsYu Zhou
Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, People’s Republic of China
6 shared publications
Latest Publications
- 4 July 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (4) , 370-373
A Novel Hemoglobin Variant, Hb Hefei [CD113(GTG > GGG)(Val > Gly); HBB :c.341T > G], Was Detected by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
Hemoglobin (Hb) variants are among the most prevalent single-gene inherited disorders. They are characterized by abnormalities in Hb’s molecular structure, typically resulting from amino acid subst...
- 4 July 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (4) , 370-373
A Novel Hemoglobin Variant, Hb Hefei [CD113(GTG > GGG)(Val > Gly); HBB :c.341T > G], Was Detected by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry
Hemoglobin (Hb) variants are among the most prevalent single-gene inherited disorders. They are characterized by abnormalities in Hb’s molecular structure, typically resulting from amino acid subst...
- Open Access
- 2 March 2026
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Performance evaluation of an automated method for accurate identification of glucose-6-phosphate dehydrogenase deficiency on the BS-2800M analyzer
The measurement of glucose-6-phosphate dehydrogenase (G6PD) activity was currently used laboratory method for the diagnosis of G6PD deficiency (G6PDd). Thi
- 2 March 2026
- Published by Springer Nature in Malaria Journal
- Vol. 25 (1)
Open AccessPerformance evaluation of an automated method for accurate identification of glucose-6-phosphate dehydrogenase deficiency on the BS-2800M analyzer
The measurement of glucose-6-phosphate dehydrogenase (G6PD) activity was currently used laboratory method for the diagnosis of G6PD deficiency (G6PDd). Thi
- 6 December 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 581, 120775
Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry
- 6 December 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 581, 120775
Rapid identification and quantification of residual daratumumab in multiple myeloma patients by MALDI - TOF mass spectrometry
- Open Access
- 16 July 2025
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 46, e00493
Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis
- 16 July 2025
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 46, e00493
Open AccessRapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis
- 3 June 2025
- Published by Taylor & Francis in Hemoglobin
- Vol. 49 (4) , 294-297
A Hemoglobin Variant, Resulting from a Novel Missense Mutation [CD 112(G14) Cys > Ser (TGT > TCT); HBB : C.338G > C], Was Discovered by MALDI-TOF MS
Here we report a hemoglobin (Hb) variant, initially detected by matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS). A 29-year-old woman who presented to our hospital for a medical examination showed a remarkable discrepancy between her fasting plasma glucose level (5.07 mmol/L) and her HbA1c value (3.61%), as determined by capillary electrophoresis (CE). Hemoglobin analysis by MALDI TOF MS revealed an abnormal globin with a mass of 15853 Da. Sanger sequencing identified a novel missense mutation in exon 112 of the β-globin chain [CD 112(G14) Cys > Ser (TGT > TCT); HBB:c.338G > C]. In reference to the birthplace of the proband, this variant was named Hb Jiangxi.
- 3 June 2025
- Published by Taylor & Francis in Hemoglobin
- Vol. 49 (4) , 294-297
A Hemoglobin Variant, Resulting from a Novel Missense Mutation [CD 112(G14) Cys > Ser (TGT > TCT); HBB : C.338G > C], Was Discovered by MALDI-TOF MS
Here we report a hemoglobin (Hb) variant, initially detected by matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS). A 29-year-old woman who presented to our hospital for a medical examination showed a remarkable discrepancy between her fasting plasma glucose level (5.07 mmol/L) and her HbA1c value (3.61%), as determined by capillary electrophoresis (CE). Hemoglobin analysis by MALDI TOF MS revealed an abnormal globin with a mass of 15853 Da. Sanger sequencing identified a novel missense mutation in exon 112 of the β-globin chain [CD 112(G14) Cys > Ser (TGT > TCT); HBB:c.338G > C]. In reference to the birthplace of the proband, this variant was named Hb Jiangxi.
- 18 April 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1773-1785
Direct screening and quantification of monoclonal immunoglobulins in serum using MALDI-TOF mass spectrometry without antibody enrichment
Objectives: Monoclonal gammopathies (MGs) are characterized by the presence of monoclonal immunoglobulins (M-proteins). Currently, recommendations for screening of MGs primarily rely on nephelometry, turbidimetry and electrophoresis, which have inherent limitations in sensitivity and throughput. This study aimed to evaluate a novel MALDI-TOF MS-based method, the intact M-protein Screening-Light Chain Assay (iMS-LC Assay), for direct M-protein detection and quantification without antibody enrichment. Methods: Residual serum samples previously analyzed via serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) were reduced to dissociate light chains from heavy chains. MALDI-TOF MS was then performed to determine the presence of M-protein characteristic pattern. The iMS-LC Assay’s analytical sensitivity, specificity, and screening efficacy in healthy populations were assessed. Results: The iMS-LC Assay successfully detected all M-proteins identified by SPE and demonstrated higher sensitivity in analytical and diagnostic studies. It accurately quantified M-proteins at concentrations below 10 g/L, with a detection limit of 0.2 g/L and the ability to detect levels below 0.1 g/L. For samples with M-protein concentrations >1 g/L, intra-assay and inter-assay coefficients of variation were <10 %. In prospective screening of M-proteins in the healthy population, the iMS-LC Assay detected M-proteins at a prevalence of 3.15 %, higher than IFE (1.87 %) and SPE (0.94 %). Conclusions: The iMS-LC Assay shows potential to replace SPE and drive advancements in the screening, diagnosis, and monitoring of MGs. Further validation of its clinical sensitivity and specificity is essential to determine its adequacy as a routine screening tool for M-proteins.
- 18 April 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (9) , 1773-1785
Direct screening and quantification of monoclonal immunoglobulins in serum using MALDI-TOF mass spectrometry without antibody enrichment
Objectives: Monoclonal gammopathies (MGs) are characterized by the presence of monoclonal immunoglobulins (M-proteins). Currently, recommendations for screening of MGs primarily rely on nephelometry, turbidimetry and electrophoresis, which have inherent limitations in sensitivity and throughput. This study aimed to evaluate a novel MALDI-TOF MS-based method, the intact M-protein Screening-Light Chain Assay (iMS-LC Assay), for direct M-protein detection and quantification without antibody enrichment. Methods: Residual serum samples previously analyzed via serum protein electrophoresis (SPE) and immunofixation electrophoresis (IFE) were reduced to dissociate light chains from heavy chains. MALDI-TOF MS was then performed to determine the presence of M-protein characteristic pattern. The iMS-LC Assay’s analytical sensitivity, specificity, and screening efficacy in healthy populations were assessed. Results: The iMS-LC Assay successfully detected all M-proteins identified by SPE and demonstrated higher sensitivity in analytical and diagnostic studies. It accurately quantified M-proteins at concentrations below 10 g/L, with a detection limit of 0.2 g/L and the ability to detect levels below 0.1 g/L. For samples with M-protein concentrations >1 g/L, intra-assay and inter-assay coefficients of variation were <10 %. In prospective screening of M-proteins in the healthy population, the iMS-LC Assay detected M-proteins at a prevalence of 3.15 %, higher than IFE (1.87 %) and SPE (0.94 %). Conclusions: The iMS-LC Assay shows potential to replace SPE and drive advancements in the screening, diagnosis, and monitoring of MGs. Further validation of its clinical sensitivity and specificity is essential to determine its adequacy as a routine screening tool for M-proteins.
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (6) , 1383-1404
Single-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV
Objectives: The tumorigenic progression of Lung adenocarcinoma (LUAD), the predominant NSCLC subtype, is predominantly driven by co-occurring mutations in KRAS proto-oncogene (KRAS)/Tumor protein p53 (TP53). However, their i... | Find, read and cite all the research you need on Tech Science Press
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (6) , 1383-1404
Open AccessSingle-Cell Transcriptomic Profiling Reveals KRAS/TP53-Driven Neutrophil Reprogramming in Luad: A Multi-Gene Prognostic Model and Therapeutic Targeting of RHOV
Objectives: The tumorigenic progression of Lung adenocarcinoma (LUAD), the predominant NSCLC subtype, is predominantly driven by co-occurring mutations in KRAS proto-oncogene (KRAS)/Tumor protein p53 (TP53). However, their i... | Find, read and cite all the research you need on Tech Science Press
- 27 May 2024
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 55 (6) , 708-712
Interference of hemoglobin variants with HbA1c measurements by six commonly used HbA1c methods
Background: Glycated hemoglobin, or hemoglobin A1c (HbA1c), serves as a crucial marker for diagnosing diabetes and monitoring its progression. We aimed to assess the interference posed by common Hb variants on popular HbA1c measurement systems. Methods: A total of 63 variant and nonvariant samples with target values assigned by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-calibrated methods were included. We assessed 6 methods for measuring HbA1c in the presence of HbS, HbC, HbD, HbE, and fetal hemoglobin (HbF): 2 cation-exchange high-performance liquid chromatography (HPLC) methods (Bio-Rad D-100 and HLC-723 G8), a capillary electrophoresis (CE) method (Sebia Capillarys 3 TERA), an immunoassay (Roche c501), an enzyme assay system (Mindray BS-600M), and a boronate affinity method (Primus Premier Hb9210). Results: The HbA1c results for nonvariant samples from the 6 methods were in good agreement with the IFCC-calibrated method results. The Bio-Rad D-100, Capillarys 3, Mindray BS-600M, Premier Hb9210, and Roche c501 showed no interference from HbS, HbC, HbD, and HbE. Clinically significant interference was observed for the HLC-723 G8 standard mode. Elevated HbF levels caused significant negative biases for all 6 methods, which increased with increasing HbF concentration. Conclusion: Elevated levels of HbF can severely affect HbA1c measurements by borate affinity, immunoassays, and enzyme assays.
- 27 May 2024
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 55 (6) , 708-712
Interference of hemoglobin variants with HbA1c measurements by six commonly used HbA1c methods
Background: Glycated hemoglobin, or hemoglobin A1c (HbA1c), serves as a crucial marker for diagnosing diabetes and monitoring its progression. We aimed to assess the interference posed by common Hb variants on popular HbA1c measurement systems. Methods: A total of 63 variant and nonvariant samples with target values assigned by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)-calibrated methods were included. We assessed 6 methods for measuring HbA1c in the presence of HbS, HbC, HbD, HbE, and fetal hemoglobin (HbF): 2 cation-exchange high-performance liquid chromatography (HPLC) methods (Bio-Rad D-100 and HLC-723 G8), a capillary electrophoresis (CE) method (Sebia Capillarys 3 TERA), an immunoassay (Roche c501), an enzyme assay system (Mindray BS-600M), and a boronate affinity method (Primus Premier Hb9210). Results: The HbA1c results for nonvariant samples from the 6 methods were in good agreement with the IFCC-calibrated method results. The Bio-Rad D-100, Capillarys 3, Mindray BS-600M, Premier Hb9210, and Roche c501 showed no interference from HbS, HbC, HbD, and HbE. Clinically significant interference was observed for the HLC-723 G8 standard mode. Elevated HbF levels caused significant negative biases for all 6 methods, which increased with increasing HbF concentration. Conclusion: Elevated levels of HbF can severely affect HbA1c measurements by borate affinity, immunoassays, and enzyme assays.
- 5 March 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (10) , 2082-2090
Evaluation of effects from hemoglobin variants on HbA1c measurements by different methods
Objectives: The impact of seven hemoglobin variants (Hb Q-Thailand, Hb G-Honolulu, Hb Ube-2, Hb New York, Hb J-Bangkok, Hb G-Coushatta, and Hb E) on the outcome of HbA1c was investigated for six methods by comparing with liquid chromatography-tandem mass spectrometry (LC/MS/MS) reference method. Methods: Twenty-nine normal and 112 variant samples were measured by LC/MS/MS, Sebia Capillarys 3 TERA, Intelligene Biosystems QuanTOF, Premier Hb9210, Arkray HA-8190V, Bio-Rad D-100, and Tosoh G11, then evaluated for correlation, consistency, and mean relative bias among six methods. The lowest biological variation bias of ±2.8 % was an acceptable standard. Results: All methods showed poor correlation and consistency with LC/MS/MS for Hb E. The unacceptable biases were observed for Capillarys 3 TERA (−14.4 to −3.7 % for Hb Q-Thailand, Hb Ube-2, Hb New York, Hb J-Bangkok and Hb E), QuanTOF (−8.3 to −2.9 % for Hb Ube-2, Hb New York and Hb G-Coushatta), Premier Hb9210 (−18.3 to −3.6 % for Hb Q-Thailand, Hb Ube-2, Hb New York, Hb J-Bangkok and Hb E), HA-8190V variant mode (−17.3 to 6.6 % for Hb G-Honolulu, Hb Ube-2, Hb New York, Hb G-Coushatta and Hb E). All variant samples showed larger biases than ±2.8 % comparing HA-8190V fast mode, D-100, and G11 with LC/MS/MS. Conclusions: The accuracy of different HbA1c methods was influenced by some Hb variants, especially Hb Ube-2 and Hb New York. Thus, laboratories need to choose appropriate methods to measure HbA1c with different Hb variants.
- 5 March 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 62 (10) , 2082-2090
Evaluation of effects from hemoglobin variants on HbA1c measurements by different methods
Objectives: The impact of seven hemoglobin variants (Hb Q-Thailand, Hb G-Honolulu, Hb Ube-2, Hb New York, Hb J-Bangkok, Hb G-Coushatta, and Hb E) on the outcome of HbA1c was investigated for six methods by comparing with liquid chromatography-tandem mass spectrometry (LC/MS/MS) reference method. Methods: Twenty-nine normal and 112 variant samples were measured by LC/MS/MS, Sebia Capillarys 3 TERA, Intelligene Biosystems QuanTOF, Premier Hb9210, Arkray HA-8190V, Bio-Rad D-100, and Tosoh G11, then evaluated for correlation, consistency, and mean relative bias among six methods. The lowest biological variation bias of ±2.8 % was an acceptable standard. Results: All methods showed poor correlation and consistency with LC/MS/MS for Hb E. The unacceptable biases were observed for Capillarys 3 TERA (−14.4 to −3.7 % for Hb Q-Thailand, Hb Ube-2, Hb New York, Hb J-Bangkok and Hb E), QuanTOF (−8.3 to −2.9 % for Hb Ube-2, Hb New York and Hb G-Coushatta), Premier Hb9210 (−18.3 to −3.6 % for Hb Q-Thailand, Hb Ube-2, Hb New York, Hb J-Bangkok and Hb E), HA-8190V variant mode (−17.3 to 6.6 % for Hb G-Honolulu, Hb Ube-2, Hb New York, Hb G-Coushatta and Hb E). All variant samples showed larger biases than ±2.8 % comparing HA-8190V fast mode, D-100, and G11 with LC/MS/MS. Conclusions: The accuracy of different HbA1c methods was influenced by some Hb variants, especially Hb Ube-2 and Hb New York. Thus, laboratories need to choose appropriate methods to measure HbA1c with different Hb variants.
- 15 February 2024
- Vol. 14 (2) , 655-678
Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing.
Lung cancer stands as the predominant cause of cancer-related mortality globally. Lung adenocarcinoma (LUAD), being the most prevalent subtype, garners extensive attention due to its notable heterogeneity, which significantly influences tumor development and treatment approaches. This research leverages single-cell RNA sequencing (scRNA-seq) datasets to delve into the impact of KRAS/TP53 co-mutation status on LUAD. Moreover, utilizing the TCGA-LUAD dataset, we formulated a novel predictive risk model, comprising seven prognostic genes, through LASSO regression, and subjected it to both internal and external validation sets. The study underscores the profound impact of KRAS/TP53 co-mutational status on the tumor microenvironment (TME) of LUAD. Crucially, KRAS/TP53 co-mutation markedly influences the extent of B cell infiltration and various immune-related pathways within the TME. The newly developed predictive risk model exhibited robust performance across both internal and external validation sets, establishing itself as a viable independent prognostic factor. Additionally, in vitro experiments indicate that MELTF and PLEK2 can modulate the invasion and proliferation of human non-small cell lung cancer cells. In conclusion, we elucidated that KRAS/TP53 co-mutations may modulate TME and patient prognosis by orchestrating B cells and affiliated pathways. Furthermore, we spotlight that MELTF and PLEK2 not only function as prognostic indicators for LUAD, but also lay the foundation for the exploration of innovative therapeutic approaches.
- 15 February 2024
- Vol. 14 (2) , 655-678
Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing.
Lung cancer stands as the predominant cause of cancer-related mortality globally. Lung adenocarcinoma (LUAD), being the most prevalent subtype, garners extensive attention due to its notable heterogeneity, which significantly influences tumor development and treatment approaches. This research leverages single-cell RNA sequencing (scRNA-seq) datasets to delve into the impact of KRAS/TP53 co-mutation status on LUAD. Moreover, utilizing the TCGA-LUAD dataset, we formulated a novel predictive risk model, comprising seven prognostic genes, through LASSO regression, and subjected it to both internal and external validation sets. The study underscores the profound impact of KRAS/TP53 co-mutational status on the tumor microenvironment (TME) of LUAD. Crucially, KRAS/TP53 co-mutation markedly influences the extent of B cell infiltration and various immune-related pathways within the TME. The newly developed predictive risk model exhibited robust performance across both internal and external validation sets, establishing itself as a viable independent prognostic factor. Additionally, in vitro experiments indicate that MELTF and PLEK2 can modulate the invasion and proliferation of human non-small cell lung cancer cells. In conclusion, we elucidated that KRAS/TP53 co-mutations may modulate TME and patient prognosis by orchestrating B cells and affiliated pathways. Furthermore, we spotlight that MELTF and PLEK2 not only function as prognostic indicators for LUAD, but also lay the foundation for the exploration of innovative therapeutic approaches.